Hims & Hers Health Inc. (HIMS)

I remain bullish on Hims & Hers Health due to its resilient subscriber growth and strong positioning in the expanding personalized care and telehealth markets. Despite the loss of the GLP-1 contract w...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

The technology sector can be one of the best places to invest your money. With the digitalization trend gaining popularity and the rapid advancements taking place in artificial intelligence, the secto...

Most investors have noticed that most stocks in the healthcare sector have declined to levels not seen in a while, making this an area of interest for those looking into the next potential upswing in ...

Hims & Hers is undervalued, rapidly scaling a vertically integrated, consumer-focused healthcare platform with 73% YoY revenue growth and strong EBITDA margins. Market fears over GLP-1 regulatory chan...

HIMS eyes long-term growth with new hormonal health offerings, international expansion and high GLP-1 retention.

Insider trading activity often serves as a window into how company executives view their own businesses. When insiders buy, it can signal confidence in future growth; when they sell, it may raise ques...

Share prices of GoodRx (NASDAQ: GDRX), the American healthcare company and telemedicine service, are currently soaring after the company announced that it will partner with Novo Nordisk to offer the l...

Hims & Hers posted 73% year-over-year revenue growth in Q2 2025, driven by 31% subscriber expansion and ~30% ARPU increase. Monthly online revenue per subscriber reached $74, equating to an annualized...

The U.S. Federal Trade Commission is probing complaints about Telehealth platform Hims & Hers regarding its advertising and cancellation practices, according to a Bloomberg News report citing people f...